CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice targeting Capricor Therapeutics regarding alleged securities fraud tied to its Deramiocel BLA resubmission. The release is a standard reminder for investors to seek lead plaintiff status before the September 28, 2026 deadline; the class has not yet been certified.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.